research use only

Infigratinib Phosphate FGFR inhibitor

Name: Infigratinib Phosphate
Brand: Selleck Chemicals
SKU: E4474
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E4474

Infigratinib Phosphate (NVP-BGJ398 phosphate) is the phosphate salt form of infigratinib, an orally bioavailable pan-inhibitor of human fibroblast growth factor receptors (FGFRs) with IC50 of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4 respectively. It also has potential antiangiogenic, antineoplastic and antitumor activities.

Chemical Structure

Molecular Weight: 658.47

Jump to

Quality Control

Batch: E447401 DMSO]100 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.04%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS/MSDS
Datasheet

99.04

Related Targets	EGFR VEGFR JAK PDGFR Src HIF FLT3 HER2 FLT Bcr-Abl
Other FGFR Inhibitors	PD173074 AZD4547 (Fexagratinib) BLU9931 Futibatinib (TAS-120) LY2874455 H3B-6527 PD-166866 Fisogatinib (BLU-554) Zoligratinib (Debio-1347) SSR128129E

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (151.86 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (7.59mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.250mg/ml (1.90mM)	Taking the 1 mL working solution as an example, add 50 μL of 25 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	658.47	Formula	C₂₆H₃₁Cl₂N₇O₃.H₃O₄P	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1310746-10-1	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	FGFR1 0.9 nM FGFR3 1 nM FGFR2 1.4 nM FGFR4 60 nM
References	[1] https://pubmed.ncbi.nlm.nih.gov/21936542/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-26)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07393373	ENROLLING_BY_INVITATION	Hypochondroplasia	QED Therapeutics, a BridgeBio company	2026-04-23	PHASE2
NCT05145010	ENROLLING_BY_INVITATION	Achondroplasia	QED Therapeutics, a BridgeBio company	2021-12-06	PHASE2
NCT07169279	RECRUITING	Achondroplasia	QED Therapeutics, a BridgeBio company	2025-11-19	PHASE2
NCT06926491	RECRUITING	Achondroplasia	Kyowa Kirin Co., Ltd.	2024-12-01	PHASE3
NCT05514912	WITHDRAWN	Resectable Intrahepatic Cholangiocarcinoma; Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8; Stage I Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8	Emory University	2024-03-01	PHASE2
NCT06873035	ENROLLING_BY_INVITATION	Hypochondroplasia	QED Therapeutics, a BridgeBio company	2025-04-22	PHASE2; PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):